Granata Bio – a biopharma company focused on invigorating the $3.6 billion global infertility medication market – recently announced the closing of a $14 million Series A funding round led by GV (Google Ventures). The participants in the funding round include CooperSurgical, Gedeon Richter, Alumni Ventures, Amboy Street Ventures, Vibe Bio, and others.
In the U.S., nearly 1 in 5 women struggle with infertility and are unable to get pregnant after one year of trying, according to the Centers for Disease Control and Prevention. And about 1 in 4 women in this group have difficulty getting pregnant or carrying a pregnancy to term. The problems that affect ovulation and the hormones involved with ovulation are the most common cause of female infertility and are often treated with infertility drugs as a first step. Yet very little innovation has materialized to meet this growing need.
Granata Bio launched in 2018 with the goal of invigorating the stagnant US offerings in the US fertility medication marketplace. And the company gained immediate traction by designing innovative clinical development programs to optimize outcomes for study subjects while assessing the safety and efficacy of investigational products. So far, the company has assembled a portfolio of four medications, ranging from commercialized products to early-stage developments.
Granata Bio’s leadership team brings more than 75 years of experience in fertility, with expertise in clinical development, regulatory strategy, and commercialization. Granata Bio will utilize the new capital to progress its existing pipeline, evaluate new targets, and expand the team.
KEY QUOTES:
“Despite significant growth in patient volume over the last ten years, infertility has been woefully overlooked and under-supported. We’re excited about the focus and innovation Granata Bio is bringing to this space and – most importantly – new options for patient care. We look forward to partnering with Evan Sussman and the Granata Bio team as they advance women’s health.”
— Cathy Friedman, Executive Venture Partner at GV
“Granata is taking a novel approach to both address current market dynamics and to develop unique products targeting unmet needs in women’s health. This funding is an exciting next step toward our mission of creating access for fertility patients with new therapeutic solutions.”
— CEO Evan Sussman
